DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Application/Claims/Restriction
Applicant’s election with traverse of Group I (Claims 1-3 and 11-12) in the reply filed on 10/12/2026 is acknowledged. Applicant’s traversal is on the grounds that the three groups share the common special technical features including plasma in addition to platelet lysate and the blood source being a fetal bovine or newborn calf as recited in the amended claims. Applicant argues that Johansson does not describe that the platelet lysate does not include plasma and thus teaches away from the special technical feature. This is not found persuasive because teaching away requires the prior art to criticize, discredit, or otherwise discourage the claimed solution, see MPEP § 2141.02(VI): “the prior art’s mere disclosure of more than one alternative does not constitute a teaching away from any of these alternatives because such disclosure does not criticize, discredit, or otherwise discourage the solution claimed.” Since the prior art clearly does not do this, this argument is unconvincing. Furthermore, Johansson expressly states that “platelet lysate is obtained from cell-rich plasma of bovine whole blood. It contains mainly of lysed platelets and can be used alone or in combination with other nutrient substrates” which broadly embraces the use of platelet lysate and plasma (Johansson, conclusion pg 73). Accordingly, there is a search and examination burden to search these inventions in the same application. The requirement is still deemed proper and is therefore made FINAL.
Claim 11 has been canceled. Claims 16-21 have been newly added. Claims 1-10 and 12-21 are pending. Claims 4-10, 13-15 and 17-21 are currently withdrawn with traverse from further consideration pursuant to 37 CFR 1.142 (b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-3, 12 and 16 are the subject of the present Official action.
Priority
Applicant’s claim for the benefit of a prior-filed application CN202210358313.9, 371 of PCT/CN2023/086125 filed on 4/6/2022 and 4/4/2023, respectively, under 35 U.S.C 119(e) or under 35 U.S.C 120, 121 or 365(c) is acknowledged.
Accordingly, the effective priority date of the instant application is granted as 4/6/2022.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 9/24/2024 and 10/29/2025 were received. The submission was in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement was considered by the examiner.
Claim Objections
Claim 1 describes a fetal bovine which is a 5-8 month old bovine embryo in the body of a pregnant female bovine. In cattle, the transition from an embryo to a fetus occurs around day 42 (end of the 6th week) of gestation. Thus, a 5-8 month old fetal bovine would technically be considered a fetus rather than an embryo and is objected therefore.
Claim 3 describes one or more characteristics of the serum replacement including the whole blood of the fetal bovine or newborn calf is anticoagulated, the separation is performed using a centrifugation method and the platlet lysis is performed using a freeze-thaw method. However, centrifugation and freeze-thaw methods are not “characteristics” of the serum replacement but rather processing steps which are optionally performed and is objected therefore.
Claim Interpretation
Claim 3 describes that optionally the serum replacement further has one or more of the following characteristics: the whole blood of the fetal bovine or newborn calf is anticoagulated, the separation is performed using a centrifugation method and the platelet lysis is performed using a freeze-thaw method. It is emphasized that claim scope is not limited by claim language that suggests or makes optional but does not require steps to be performed, or by claim language that does not limit a claim to a particular structure, see MPEP 2111.04. A similar analysis is applied to dependent claims 12 describing low temperature or differential centrifugation since these steps are optional and not required to be performed.
Furthermore, although the preamble describes a “serum replacement” this is considered intended use language since this merely conveys the intended purpose of the composition. If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation of significant weight, see MPEP 2111.02.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claim 1-3, 12 and 16 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter as evidenced by Bevers et al. "Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane." Physiological reviews 96.2 (2016): 605-645 (hereinafter Bevers). The claims recite naturally occurring fetal blood fractions (platelet contents plus plasma from a calf or fetus) which is a natural product.
The most recent update to the Office’s patent eligibility requirements are the 2019 Revised Patent Subject Matter Eligibility Guidance (2019 PEG) published on January 7 and October 17, 2019 (84 Fed. Reg. 50), which provides the following analysis to determine patent eligibility, derived from the decisions rendered in Mayo Collaborative Svcs. V. Prometheus Labs., 566 U.S. _, 132 S. Ct. 1289, 101 U.S.P.Q.2d 1961 (2012) (hereinafter “Mayo”), and in Alice Corp. Pty. Ltd. v CLS Bank Int’l, 573 U.S._, 134 S. Ct. 2347, 110 U.S.P.Q.2d 1976 (2014) in subsequent court cases:
Step 1 is to determine whether the claim is directed to a process, machine, manufacture, or composition of matter. If the claim is directed to a statutory category, proceed to Step 2.
Step 2 is the two-part analysis from Alice Corp.
Step 2A has been divided into 2 prongs.
Step 2A, prong 1 requires determining whether the claim is directed to the judicial exceptions of an abstract idea, a product of nature, or a law of nature or natural phenomenon other than a product of nature. To determine if the claim recites a nature-based product limitation, the markedly different characteristics analysis is use to evaluate whether the claim is directed to a “product of nature” that falls under the law of nature and natural phenomenon exceptions. In this analysis, markedly different characteristics can be expressed in terms of the product’s structure, function, and/or other properties. If YES, the claim is directed to a judicial exception, proceed to step 2A, prong 2.
Step 2A, prong 2 requires evaluating whether a judicial exception is integrated into a particular application (e.g. improving technology, effecting a particular treatment or prophylaxis, implementing with a particular machine, ect.) identified by the Supreme Court and the Federal Circuit, to ensure that the claim as a whole “integrates [the] judicial exception into a particular application [that] will apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception, such that the claim is more than a drafting effort designed to monopolize the judicial exception.”
If NO, the claim does not integrate the judicial exception into a practical application, then proceed to step 2B.
Step 2B requires analyzing whether the claim as a whole amounts to significantly more than the exception by determining whether any element, or combination of elements, in the claims is sufficient to ensure that the claim as a whole amounts to significantly more than the judicial exception. To be patent-eligible, a claim that is directed to a judicial exception must include additional features to ensure that the claim describes a process or product that applies the exception in a meaningful way, such that it is more than a drafting effort designed to monopolize the exception. The Supreme Court has identified the following non-limiting considerations for determining whether a claim with additional elements amounts to significantly more than the judicial exception itself:
Improvements to another technology or technical field;
Improvements to the functioning of the computer itself;
Applying the judicial exception with, or by use of, a particular machine;
Effecting a transformation or reduction of a particular article to a different state or thing;
Adding a specific limitation other than what is well-understood, routine and conventional in the field, or adding unconventional steps that confine the claim to a particular useful application; or
Other meaningful limitation beyond generally linking the use of the judicial exception to a particular technological environment.
Claim 1 describes a serum replacement comprising a platelet lysate and plasma derived from a fetal bovine fetus or a newborn calf. The claims are directed to one of the statutory categories and are a composition of matter (step 1). The claims are directed to a judicial exception (step 2A, prong 1) since the fetal blood fractions (platelet contents plus plasma from a calf or fetus) do not have markedly different characteristics from their natural occurring counterparts. The claims do not integrate into a particular application (step 2A, prong 2) and does not amount to significantly more than the judicial exception (step 2B). The limitations describing the fetus or calf age and feeding status are source limitations and do not convey any structure to the serum replacement itself. As described in the claim interpretation section, “serum replacement” is considered intended use language and does not create a marked difference. Platelets and plasma are naturally occurring components of mammalian blood. Although platelet lysate is recited in the claim, mammalian blood naturally contains platelet lysate since platelets naturally undergo apoptosis-like processes, including membrane blebbing which generates platelet lysate. To support this interpretation, Bevers is introduced as prior art and describes platelets that naturally undergoes apoptosis-like processes, including cell shrinkage, membrane blebbing, microvesicle shedding and phosphatidylserine exposure which generates platelet lysate in vivo (Bevers, pg 616, Fig 5, pg 619-620). With respect to claims 3 and 12, as stated in the claim interpretation section although these claims describe characteristics of the serum replacement including centrifugation and freeze thaw method, it is emphasized that these are optional and claim scope is not limited by claim language that suggests or makes optional, see MPEP 2111.04. Thus, the claims recites a naturally occurring fetal blood fractions (platelet contents plus plasma from a calf or fetus) which is a natural product and is directed to non-statutory subject matter.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-3, 12 and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Erfanmanesh et al. "Comparison of the effect of bovine platelet lysate and platelet rich plasma as growth promoters on growth rate and viability of different cell lines." (2018): 20183343118 (hereinafter Erfanmanesh) in view of Valk et al. (2018). Fetal bovine serum (FBS): Past – present – future. ALTEX. 99-118. 10.14573/altex.1705101 (hereinafter Valk).
Claims 1-3 and 16: Erfanmanesh describes a serum replacement comprising platelet lysate and plasma and compares its effect on the growth rate and viability of different cell lines in comparison to traditional fetal bovine serum (FBS) (Erfanmanesh, abstract). Erfanmanesh found that platelet lysate and plasma functioned well as a serum replacement to support cell growth (Erfanmanesh, results). Erfanmanesh describes isolating the blood from a newborn calf and centrifuging the blood to obtain a serum replacement comprising plasma and platelets. Erfanmanesh describes lysing the platelets by the freeze-thaw method (Erfanmanesh, pg 251 col 1). Erfanmanesh does not describe isolating blood from a 5-8 month old bovine fetus or newborn calf within 14 hrs of birth that has not been feed.
Claim 12: Erfanmanesh describes low temperature centrifugation at 4000g for 15 min to separate the blood cells from the platelets (Erfanmanesh, pg 251 col 1).
Claims 1-3 and 16: Valk describes FBS and serum replacement alternatives (Valk, summary). Valk states that fetal bovine serum derived from late stage (last 2/3) gestation provides blood with a low content of immunoglobulins and complement factors which prevents contamination and culturing interference (Valk, section 1.2).
It would have been prima facie obvious to one of ordinary skill in the art to use fetal bovine blood from a 5-8 month old bovine fetus as described by Valk to derive the platelet lysate and plasma in the serum replacement described by Erfanmanesh. It would have been a matter of combining known prior art elements according to yield predictable results since bovine blood can readily be extracted from 5-8 month old fetus in the body of a pregnant female bovine following the standard FBS processing steps outlined by Valk. One of ordinary skill would be motivated to start with fetal bovine blood since it contains a low content of immunoglobulins and complement factors which prevents contamination in cell culturing (Valk, section 1.2). One would have a reasonable expectation of success given that varying the starting blood sample (calf age and gestation) to obtain different blood fractions as a serum replacement is considered routine optimization since both Valk and Erfanmanesh provide evidence that these variables are known to be result-effective. See MPEP § 2144.05. Accordingly, in the absence of evidence to the contrary, one of ordinary skill in the art would have considered the claimed invention to have been prima facie obvious to at the time the invention was made.
Conclusion
No claims allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. ALEXANDER NICOL whose telephone number is (571)272-6383. The examiner can normally be reached on M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached on (571)272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Alexander Nicol
Patent Examiner
Art Unit 1634
/ALEXANDER W NICOL/Examiner, Art Unit 1634